I'm LongbridgeAI, I can summarize articles.Nuo Therapeutics reported Q2 FY26 revenue of $1.77 million, more than doubling year-over-year due to Aurix growth, with gross profit reaching $1.17 million. However, gross margin fell 11 percentage points to 66% due to Smith+Nephew transfer pricing. Operating expenses rose to $1.34 million. Six-month revenue increased 163% to $3.07 million. Supply risks emerged as Pfizer warned TJMI thrombin would be unavailable until early 2027, causing a temporary Aurix stockout in August.
- Nuo Therapeutics posted Q2 revenue of USD 1.77 million, more than doubled from a year earlier, driven by Aurix growth. * Gross profit climbed to about USD 1.17 million; gross margin fell 11 percentage points to about 66% on Smith+Nephew transfer pricing. * Operating expenses rose to about USD 1.34 million, due to higher compensation and third-party commissions; professional fees declined. * Six-month revenue rose to about USD 3.07 million, up 163% year over year; gross margin dropped 10 percentage points to about 66%. * Supply risk increased after Pfizer warned TJMI thrombin will be unavailable until early 2027, triggering a temporary Aurix out-of-stock in August. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-028053), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here